Most Recent
AstraZeneca has brought court proceedings to block Australian drug maker Pharmacor from making a generic version of its heart attack drug Brilinta.
Bayer has lost its battle to protect top-selling blood thinner Xarelto from generic competition, with the Full Court finding two patents for the drug are invalid.
The funder and law firm that ran a shareholder class action against Mayne Pharma are seeking deductions that would leave more than half of a $38 million settlement for group members.
Novartis unit Sandoz is appealing a tribunal decision in favour of pharmaceutical company Lundbeck over a licence to sell a generic version of leading antidepressant Lexapro.
Australian Clinical Labs, which is facing regulatory action over a 2022 data breach, is fighting the information commissioner's claim that it breached privacy laws 21.5 million times.
IP Australia has rejected AFT Pharmaceuticals’ bid to patent a combination cold and flu medication, finding the invention was little more than putting three different medications “in a box”.
A judge has restrained Health Services Union secretary Diana Asmar from using union cash to fund her defence against allegations of illegitimate reimbursements at the union's Victorian branch.
A judge has signed off on the eighth version of a class action against Sydney doctor Daniel Lanzer and several of his associates over allegedly negligent cosmetic surgeries.
US drug giant Eli Lilly cannot register a trade mark consisting of the word 'hair' preceded by the 'greater-than' symbol, despite winning registration in the UK, Switzerland and New Zealand.
Medibank has denied breaching privacy rules in response to the regulator's case over a 2022 cyber attack, but has admitted sensitive data was hacked in part because its network lacked multi-factor authentication.